A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
Clinical trial NCT07229872 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07229872
- Sponsor
- Harbin Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-01
- Primary completion
- 2026-12-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.